Lindsay M Morton

List of Publications by Year
in descending order

278	14,318	22146	23530
papers	citations	59 h-index	111 g-index

282	282	282	17442
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies. Journal of Clinical Oncology, 2022, 40, 1439-1449.	1.6	45
2	Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults. JAMA Network Open, 2022, 5, e223461.	5.9	16
3	Incidence of myeloid malignancies by subtype in Hong Kong and comparisons with Asian and white men and women in the United States. Leukemia and Lymphoma, 2022, 63, 1917-1924.	1.3	2
4	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology,the, 2022, 9, e374-e384.	4.6	11
5	A Novel Locus on 6p21.2 for Cancer Treatmentâ€"Induced Cardiac Dysfunction Among Childhood Cancer Survivors. Journal of the National Cancer Institute, 2022, 114, 1109-1116.	6.3	4
6	Risk of Rare Cancers Among Solid Organ Transplant Recipients. Journal of the National Cancer Institute, 2021, 113, 199-207.	6.3	17
7	Genetic variation in the body mass index of adult survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer, 2021, 127, 310-318.	4.1	6
8	Role of radiotherapy and chemotherapy in the risk of leukemia after childhood cancer: An international pooled analysis. International Journal of Cancer, 2021, 148, 2079-2089.	5.1	10
9	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study. JNCI Cancer Spectrum, 2021, 5, pkab007.	2.9	11
10	Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. British Journal of Cancer, 2021, 124, 1312-1319.	6.4	16
11	Contribution of Polygenic Risk to Hypertension Among Long-Term Survivors of Childhood Cancer. JACC: CardioOncology, 2021, 3, 76-84.	4.0	13
12	Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer. International Journal of Epidemiology, 2021, 50, 1325-1334.	1.9	4
13	The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood, 2021, 138, 785-789.	1.4	9
14	Benign Tumors in Long-Term Survivors of Retinoblastoma. Cancers, 2021, 13, 1773.	3.7	5
15	Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science, 2021, 372, .	12.6	85
16	Genetic and treatment risks for diabetes mellitus (DM) in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime (SJLIFE) cohorts.. Journal of Clinical Oncology, 2021, 39, 10014-10014.	1.6	0
17	Body mass index and survival of patients with lymphoma. Leukemia and Lymphoma, 2021, 62, 2671-2678.	1.3	5
18	Increased Risk of Skin Cancer in 1,851 Long-Term Retinoblastoma Survivors. Journal of Investigative Dermatology, 2021, 141, 2849-2857.e3.	0.7	6

#	Article	IF	Citations
19	Clinical and genetic risk factors for radiationâ€associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer, 2021, 127, 4091-4102.	4.1	6
20	Polygenic Risk Score Improves Risk Stratification and Prediction of Subsequent Thyroid Cancer after Childhood Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2096-2104.	2.5	11
21	Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 937.e1-937.e7.	1.2	5
22	Causeâ€specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001â€“2017. American Journal of Hematology, 2021, 96, E451-E454.	4.1	8
23	Assessment of surveillance versus etiologic factors in the reciprocal association between papillary thyroid cancer and breast cancer. Cancer Epidemiology, 2021, 74, 101985.	1.9	1
24	Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. Journal of the American Academy of Dermatology, 2020, 83, 762-772.	1.2	7
25	Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015. Cancer Epidemiology, 2020, 64, 101664.	1.9	20
26	Cancer risk following lymphoid malignancies among HIV-infected people. Aids, 2020, 34, 1237-1245.	2.2	10
27	Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer. Radiotherapy and Oncology, 2020, 151, 33-39.	0.6	13
28	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367
29	Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma. PLoS ONE, 2020, 15, e0237792.	2.5	6
30	Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016. Journal of Clinical Oncology, 2020, 38, 4149-4162.	1.6	29
31	Subsequent Neoplasm Risk Associated With Rare Variants in DNA Damage Response and Clinical Radiation Sensitivity Syndrome Genes in the Childhood Cancer Survivor Study. JCO Precision Oncology, 2020, 4, 926-936.	3.0	9
32	Racial and ethnic differences in risk of second primary cancers among prostate cancer survivors. Cancer Causes and Control, 2020, 31, 1011-1019.	1.8	3
33	Generalizability of â€œGWAS Hitsâ€•in Clinical Populations: Lessons from Childhood Cancer Survivors. American Journal of Human Genetics, 2020, 107, 636-653.	6.2	12
34	Subsequent Primary Neoplasms. Pediatric Clinics of North America, 2020, 67, 1135-1154.	1.8	16
35	The Future of Childhood Cancer Survivorship. Pediatric Clinics of North America, 2020, 67, 1237-1251.	1.8	17
36	Testicular Cancer as a Model for Understanding the Impact of Evolving Treatment Strategies on the Long-Term Health of Cancer Survivors. JNCI Cancer Spectrum, 2020, 4, pkaa013.	2.9	3

#	Article	IF	Citations
37	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncology, 2020, 6, 724.	7.1	139
38	Causeâ€specific mortality in individuals with lymphoplasmacytic lymphoma/WaldenstrÃ¶m macroglobulinaemia, 2000â€“2016. British Journal of Haematology, 2020, 189, 1107-1118.	2.5	8
39	Genetic variation in POT1 and risk of thyroid subsequent malignant neoplasm: A report from the Childhood Cancer Survivor Study. PLoS ONE, 2020, 15, e0228887.	2.5	18
40	Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors. Journal of Clinical Oncology, 2020, 38, 1648-1650.	1.6	0
41	Genome-wide Association Studies Reveal Novel Locus With Sex-/Therapy-Specific Fracture Risk Effects in Childhood Cancer Survivors. Journal of Bone and Mineral Research, 2020, 36, 685-695.	2.8	7
42	Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. Ophthalmology, 2020, 127, 1549-1557.	5.2	24
43	Using patient-reported outcomes to improve survivorship care. Blood, 2020, 135, 1819-1820.	1.4	2
44	Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the childhood cancer survivor study and the St. Jude Lifetime Cohort.. Journal of Clinical Oncology, 2020, 38, 10550-10550.	1.6	0
45	HAGHL genetic variants increase first fracture risk (FFR) in female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort Study (SJLIFE).. Journal of Clinical Oncology, 2020, 38, 10554-10554.	1.6	0
46	Abstract 1056: Elevated incidence of rare cancers among solid organ transplant recipients (SOTRs) in the United States. , 2020, , .		0
47	Abstract 5703: Oncologic therapy shapes the fitness landscape of clonal hematopoiesis. , 2020, , .		0
48	Body Mass Index and Survival of Patients with Lymphoma. Blood, 2020, 136, 2-3.	1.4	0
49	Title is missing!. , 2020, 15, e0228887.		0
50	Title is missing!. , 2020, 15, e0228887.		0
51	Title is missing!. , 2020, 15, e0228887.		0
52	Title is missing!. , 2020, 15, e0228887.		0
53	Title is missing!. , 2020, 15, e0237792.		0
54	Title is missing!. , 2020, 15, e0237792.		0

#	Article	IF	Citations
55	Title is missing!. , 2020, 15, e0237792.		0
56	Title is missing!. , 2020, 15, e0237792.		0
57	Genetic overlap between autoimmune diseases and nonâ€Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863.	1.3	28
58	Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study. Leukemia, 2019, 33, 2947-2978.	7.2	17
59	Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 2019, 37, 2120-2130.	1.6	35
60	Bone and Softâ€Tissue Sarcoma Risk in Longâ€Term Survivors of Hereditary Retinoblastoma Treated With Radiation. Journal of Clinical Oncology, 2019, 37, 3436-3445.	1.6	19
61	Association of Breast Cancer Risk After Childhood Cancer With Radiation Dose to the Breast and Anthracycline Use. JAMA Pediatrics, 2019, 173, 1171.	6.2	40
62	Risk of Second Primary Bone and Softâ€“Tissue Sarcomas Among Young Adulthood Cancer Survivors. JNCI Cancer Spectrum, 2019, 3, pkz043.	2.9	7
63	Patterns of Cause-Specific Mortality Among 2053 Survivors of Retinoblastoma, 1914â€“2016. Journal of the National Cancer Institute, 2019, 111, 961-969.	6.3	26
64	Genome-Wide Association Study in Irradiated Childhood Cancer Survivors Identifies HTR2A forÂSubsequent Basal Cell Carcinoma. Journal of Investigative Dermatology, 2019, 139, 2042-2045.e8.	0.7	18
65	Sex-Related Effect on Immunotherapy Response: Implications and Opportunities. Journal of the National Cancer Institute, 2019, 111, 749-750.	6.3	5
66	Cancer risk following postâ€transplant lymphoproliferative disorders in solid organ transplant recipients. British Journal of Haematology, 2019, 186, 347-351.	2.5	4
67	Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes. Blood Advances, 2019, 3, 1961-1969.	5.2	12
68	Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. JAMA Oncology, 2019, 5, 318.	7.1	116
69	Telomere Length-Associated Genetic Variants and the Risk of Thyroid Cancer in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS). Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 417-419.	2.5	7
70	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. Frontiers in Oncology, 2019, 9, 1539.	2.8	6
71	Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A COG-ALTE03N1 and CCSS report.. Journal of Clinical Oncology, 2019, 37, 10015-10015.	1.6	5
72	Subsequent neoplasm risk associated with rare variants in DNA repair and clinical radiation sensitivity syndrome genes: A report from the Childhood Cancer Survivor Study.. Journal of Clinical Oncology, 2019, 37, 10028-10028.	1.6	1

#	Article	IF	Citations
73	Genome-wide association study using whole-genome sequencing to identify a novel locus associated with cardiomyopathy risk in adult survivors of childhood cancer: Utility of a two-stage analytic approach.. Journal of Clinical Oncology, 2019, 37, 1516-1516.	1.6	0
74	Polygenic risk of subsequent thyroid cancer after childhood cancer: A report from St. Jude lifetime cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS).. Journal of Clinical Oncology, 2019, 37, 10060-10060.	1.6	0
75	Combined effect of radiotherapy and anthracyclines on risk of breast cancer among female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).. Journal of Clinical Oncology, 2019, 37, 10053-10053.	1.6	0
76	Cause-specific mortality in survivors of lymphoplasmacytic lymphoma (LPL) and waldenstrom macroglobulinemia (WM).. Journal of Clinical Oncology, 2019, 37, e19056-e19056.	1.6	0
77	Abstract LB-304: Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis. , 2019, , .		0
78	Abstract 3122: A functionalPOT1variant and risk of thyroid subsequent malignant neoplasm: A report from the Childhood Cancer Survivor Study. , 2019, , .		0
79	Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015. Blood, 2019, 134, 4034-4034.	1.4	0
80	Comparison of Radiation Dose Reconstruction Methods to Investigate Late Adverse Effects of Radiotherapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Radiation Research, 2019, 193, 95.	1.5	4
81	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood, 2018, 131, 2541-2551.	1.4	21
82	Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival. Journal of the National Cancer Institute, 2018, 110, 1248-1258.	6.3	15
83	A High-risk Haplotype for Premature Menopause in Childhood Cancer Survivors Exposed to Gonadotoxic Therapy. Journal of the National Cancer Institute, 2018, 110, 895-904.	6.3	19
84	Association of Treatment for Hodgkin Lymphoma With Estrogen Receptor Status of Subsequent Breast Cancers. JAMA Oncology, 2018, 4, 414.	7.1	7
85	Successful use of whole genome amplified DNA from multiple source types for high-density Illumina SNP microarrays. BMC Genomics, 2018, 19, 182.	2.8	16
86	A NOVEL METHOD TO ESTIMATE LYMPHOCYTE DOSE AND APPLICATION TO PEDIATRIC AND YOUNG ADULT CT PATIENTS IN THE UNITED KINGDOM. Radiation Protection Dosimetry, 2018, 178, 116-121.	0.8	6
87	Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 775-786.	3.8	12
88	Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review. Journal of Clinical Oncology, 2018, 36, 2145-2152.	1.6	105
89	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. Genome Medicine, 2018, 10, 99.	8.2	15
90	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia. Nature Communications, 2018, 9, 4182.	12.8	15

#	Article	IF	Citations
91	Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000â€“2014. Leukemia, 2018, 32, 2580-2589.	7.2	22
92	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research, 2018, 78, 4086-4096.	0.9	34
93	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. Nature Communications, 2018, 9, 3184.	12.8	50
94	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology,the, 2018, 5, e563-e598.	4.6	97
95	Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis. Blood, 2018, 132, 747-747.	1.4	3
96	Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy. International Journal of Particle Therapy, 2018, 5, 103-113.	1.8	6
97	Abstract 2970: Multiple new susceptibility loci identified in genome-wide association study of Ewing sarcoma. , 2018, , .		0
98	Abstract 2966: A genome-wide scan identifies a new locus associated with pediatric rhabdomyosarcoma. , 2018, , .		0
99	Abstract 600: Telomere length-associated genetic variants and the risk of thyroid cancer after childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). , 2018, , .		0
100	Abstract A13: Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. , 2018, , .		0
101	Risk Factors for the Development of Cutaneous Melanoma after Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 249-249.	1.4	0
102	No Association between Radiation Dose from Pediatric CT Scans and Risk of Subsequent Hodgkin Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 804-806.	2.5	19
103	Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. Radiation Research, 2017, 187, 186.	1.5	13
104	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175.	12.8	75
105	Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	66
106	Risk of Second Malignancies in Solid Organ Transplant Recipients Who Develop Keratinocyte Cancers. Cancer Research, 2017, 77, 4196-4203.	0.9	22
107	Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers. Breast Cancer Research and Treatment, 2017, 166, 299-306.	2.5	19
108	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187.	2.7	15

#	Article	IF	Citations
109	RE: The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study. Journal of the National Cancer Institute, 2017, 109, .	6.3	0
110	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 367-378.	2.0	50
111	Breast Cancer After Childhood, Adolescent, and Young Adult Cancer: Itâ€™s Not Just About Chest Radiation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 736-745.	3.8	2
112	A high-risk genetic profile for premature menopause (PM) in childhood cancer survivors (CCS) exposed to gonadotoxic therapy: A report from the St. Jude Lifetime Cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS).. Journal of Clinical Oncology, 2017, 35, 10502-10502.	1.6	1
113	Risk of subsequent breast cancer after radiotherapy according to hormone-receptor status: A nested case-control study in the Childhood Cancer Survivor Study (CCSS).. Journal of Clinical Oncology, 2017, 35, 10520-10520.	1.6	0
114	Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013. , 2017, , .		0
115	Abstract 1318: A genome-wide association study of WaldenstrÃ¶m macroglobulinemia/lymphoplasmacytic lymphoma demonstrates association with chromosome 6. , 2017, , .		0
116	HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation. Transplantation, 2016, 100, 2453-2460.	1.0	17
117	Trends in primary central nervous system lymphoma incidence and survival in the U.S.. British Journal of Haematology, 2016, 174, 417-424.	2.5	196
118	Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001â€“12. British Journal of Haematology, 2016, 174, 382-396.	2.5	142
119	Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims (â€œMedWASâ€). Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1105-1113.	2.5	23
120	Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States, 2001â¿¿2010. Cancer Epidemiology, 2016, 42, 15-23.	1.9	39
121	Increased pancreatic cancer risk following radiotherapy for testicular cancer. British Journal of Cancer, 2016, 115, 901-908.	6.4	30
122	2016 US lymphoid malignancy statistics by World Health Organization subtypes. Ca-A Cancer Journal for Clinicians, 2016, 66, 443-459.	329.8	791
123	Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer. JAMA Oncology, 2016, 2, 1368.	7.1	30
124	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	12.8	94
125	Polycyclic aromatic hydrocarbons: determinants of residential carpet dust levels and risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2016, 27, 1-13.	1.8	20
126	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Human Molecular Genetics, 2016, 25, 1663-1676.	2.9	52

#	Article	IF	Citations
127	Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 174-179.	2.5	52
128	Spectrum of pediatric and young adult cancer survivors at risk of developing subsequent sarcomas.. Journal of Clinical Oncology, 2016, 34, 10572-10572.	1.6	0
129	Genome-wide association study of meningioma as a subsequent neoplasm: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort (SJLIFE).. Journal of Clinical Oncology, 2016, 34, 10510-10510.	1.6	0
130	Abstract 2691: Genome-wide association study identifies two susceptibility loci that modify radiation-related risk for breast cancer after childhood cancer: A report from the Childhood Cancer Survivor Study and St. Jude Lifetime Cohort. , 2016, , .		0
131	Abstract 5206: Recent incidence trends of lymphoid malignancies in Hong Kong, 2001-2010. , 2016, , .		0
132	Abstract 5207: Comparison of subtype-specific incidence rates of lymphoid malignancies in Hong Kong and the United States. , 2016, , .		0
133	Investigation of spatio-temporal cancer clusters using residential histories in a caseâ€“control study of non-Hodgkin lymphoma in the United States. Environmental Health, 2015, 14, 48.	4.0	8
134	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751.	12.8	58
135	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1061-1070.	2.5	8
136	Risk of Second Cancers According to Radiation Therapy Technique and Modality in Prostate Cancer Survivors. International Journal of Radiation Oncology Biology Physics, 2015, 91, 295-302.	0.8	48
137	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. American Journal of Epidemiology, 2015, 181, 406-421.	3.4	54
138	Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nature Genetics, 2015, 47, 1073-1078.	21.4	157
139	Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2015, 33, 3096-3104.	1.6	26
140	Second Tumors in Retinoblastoma Survivors. Essentials in Ophthalmology, 2015, , 105-112.	0.1	0
141	Abstract 3725: Subsequent gastrointestinal cancer risks of childhood and early adulthood cancer survivors. , 2015, , .		0
142	Abstract LB-184: Risk factors for lung cancer among survivors of non-Hodgkin lymphoma. , 2015, , .		0
143	Abstract 934: A pooled investigation of circulating adiponectin levels and risk of multiple myeloma. , 2015, , .		0
144	Incidence and Patient Survival of Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) in the United States: A Population-Based View of the Modern Diagnostic Era. Blood, 2015, 126, 2806-2806.	1.4	0

#	Article	IF	Citations
145	Emerging Risks of AML/MDS and Other Myeloid Neoplasms Following Chemotherapy for First Primary Malignancy, 2000-2012. Blood, 2015, 126, 562-562.	1.4	1
146	The Rising Incidence of Second Cancers: Patterns of Occurrence and Identification of Risk Factors for Children and Adults. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e57-e67.	3.8	129
147	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Diffuse Large B-Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 15-25.	2.1	98
148	Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 1-14.	2.1	52
149	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mycosis Fungoides and Sezary Syndrome: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 98-105.	2.1	42
150	Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era. Leukemia and Lymphoma, 2014, 55, 551-557.	1.3	24
151	Medical History, Lifestyle, and Occupational Risk Factors for Hairy Cell Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 115-124.	2.1	31
152	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Follicular Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 26-40.	2.1	151
153	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Adult Acute Lymphocytic Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 125-129.	2.1	16
154	Cigarette Smoking Prior to First Cancer and Risk of Second Smoking-Associated Cancers Among Survivors of Bladder, Kidney, Head and Neck, and Stage I Lung Cancers. Journal of Clinical Oncology, 2014, 32, 3989-3995.	1.6	93
155	Pooling Prospective Studies to Investigate the Etiology of Second Cancers. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1598-1608.	2.5	9
156	Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era. Aids, 2014, 28, 2313-2318.	2.2	150
157	Prevalence of HIV Infection among U.S. Hodgkin Lymphoma Cases. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 274-281.	2.5	59
158	Hepatitis B or C virus infection and risk of non-Hodgkin lymphoma among solid organ transplant recipients. Haematologica, 2014, 99, 70-73.	3.5	64
159	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Marginal Zone Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 52-65.	2.1	70
160	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Peripheral T-Cell Lymphomas: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 66-75.	2.1	52
161	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 87-97.	2.1	32
162	Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. British Journal of Haematology, 2014, 165, 67-77.	2.5	127

#	Article	IF	Citations
163	Risk of diffuse large Bâ€cell lymphoma after solid organ transplantation in the United States. American Journal of Hematology, 2014, 89, 714-720.	4.1	37
164	Differences in incidence and trends of haematological malignancies in <scp>J</scp>apan and the <scp>U</scp>nited <scp>S</scp>tates. British Journal of Haematology, 2014, 164, 536-545.	2.5	250
165	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 130-144.	2.1	265
166	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	21.4	147
167	Body Mass Index and Risk of Second Obesity-Associated Cancers After Colorectal Cancer: A Pooled Analysis of Prospective Cohort Studies. Journal of Clinical Oncology, 2014, 32, 4004-4011.	1.6	56
168	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Sporadic Burkitt Lymphoma/Leukemia: The Interlymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 106-114.	2.1	32
169	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	6.2	96
170	Risk of Subsequent Malignant Neoplasms in Long-Term Hereditary Retinoblastoma Survivors After Chemotherapy and Radiotherapy. Journal of Clinical Oncology, 2014, 32, 3284-3290.	1.6	103
171	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 76-86.	2.1	31
172	Current knowledge and future research directions in treatment-related second primary malignancies. European Journal of Cancer, Supplement, 2014, 12, 5-17.	2.2	59
173	Triple jeopardy for Hodgkin lymphoma survivors?. Blood, 2014, 124, 309-310.	1.4	2
174	Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica, 2014, 99, e193-e196.	3.5	37
175	Risk factors for melanoma among survivors of non-Hodgkin lymphoma in the U.S. elderly population.. Journal of Clinical Oncology, 2014, 32, 1533-1533.	1.6	0
176	Risk of subsequent malignant neoplasms in long-term retinoblastoma survivors following chemotherapy and radiotherapy.. Journal of Clinical Oncology, 2014, 32, 10079-10079.	1.6	0
177	Radiation Dose and Subsequent Risk for Stomach Cancer in Long-term Survivors of Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 86, 922-929.	0.8	23
178	Second Solid Cancers After Radiation Therapy: A Systematic Review of the Epidemiologic Studies of the Radiation Dose-Response Relationship. International Journal of Radiation Oncology Biology Physics, 2013, 86, 224-233.	0.8	220
179	Residential proximity to industrial combustion facilities and risk of non-Hodgkin lymphoma: a caseâ€“control study. Environmental Health, 2013, 12, 20.	4.0	28
180	Prediction of the location and size of the stomach using patient characteristics for retrospective radiation dose estimation following radiotherapy. Physics in Medicine and Biology, 2013, 58, 8739-8753.	3.0	11

#	Article	IF	Citations
181	Dissecting lymphoma incidence to inform epidemiologic and clinical research. Leukemia and Lymphoma, 2013, 54, 1575-1576.	1.3	6
182	Risk of non-Hodgkin lymphoma after radiotherapy for solid cancers. Leukemia and Lymphoma, 2013, 54, 1691-1697.	1.3	28
183	Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. Cancer Causes and Control, 2013, 24, 125-134.	1.8	20
184	Household endotoxin levels and the risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2013, 24, 357-364.	1.8	4
185	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876.	21.4	179
186	Radiation Dose to the Esophagus From Breast Cancer Radiation Therapy, 1943-1996: An International Population-Based Study of 414 Patients. International Journal of Radiation Oncology Biology Physics, 2013, 86, 694-701.	0.8	13
187	Lifestyle and Dietary Factors in Relation to Risk of Chronic Myeloid Leukemia in the NIH-AARP Diet and Health Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 848-854.	2.5	39
188	Leveraging Epidemiology and Clinical Studies of Cancer Outcomes: Recommendations and Opportunities for Translational Research. Journal of the National Cancer Institute, 2013, 105, 85-94.	6.3	46
189	Burkitt lymphoma risk in U.S. solid organ transplant recipients. American Journal of Hematology, 2013, 88, 245-250.	4.1	28
190	Plasma Cell Neoplasms in US Solid Organ Transplant Recipients. American Journal of Transplantation, 2013, 13, 1523-1532.	4.7	34
191	Stomach Cancer Risk After Treatment for Hodgkin Lymphoma. Journal of Clinical Oncology, 2013, 31, 3369-3377.	1.6	96
192	The Epidemic of Nonâ€“Hodgkin Lymphoma in the United States: Disentangling the Effect of HIV, 1992â€“2009. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1069-1078.	2.5	95
193	Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood, 2013, 121, 2996-3004.	1.4	195
194	Shedding light on UVR and Hodgkin lymphoma. Blood, 2013, 122, 3395-3397.	1.4	0
195	Sex- and Subtype-Specific Analysis of H2AFX Polymorphisms in Non-Hodgkin Lymphoma. PLoS ONE, 2013, 8, e74619.	2.5	1
196	Abstract 1333: Specific RB1 mutations and risk of subsequent neoplasms among survivors of hereditary retinoblastoma.. , 2013, , .		0
197	Stomach cancer risk following radiotherapy for testicular cancer.. Journal of Clinical Oncology, 2013, 31, 4536-4536.	1.6	9
198	LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Leukemia and Lymphoma, 2012, 53, 1105-1112.	1.3	5

#	Article	IF	Citations
199	Risk of treatment-related esophageal cancer among breast cancer survivors. Annals of Oncology, 2012, 23, 3081-3091.	1.2	71
200	Converting Epidemiologic Studies of Cancer Etiology to Survivorship Studies: Approaches and Challenges. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 875-880.	2.5	17
201	PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium. Blood, 2012, 120, 4645-4648.	1.4	34
202	Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood, 2012, 119, 34-43.	1.4	498
203	Smoking and lymphoma: a small part of a complex story. Leukemia and Lymphoma, 2012, 53, 1853-1854.	1.3	3
204	Meat Intake Is Not Associated with Risk of Non-Hodgkin Lymphoma in a Large Prospective Cohort of U.S. Men and Women. Journal of Nutrition, 2012, 142, 1074-1080.	2.9	32
205	Inherited genetic variation and overall survival following follicular lymphoma. American Journal of Hematology, 2012, 87, 724-726.	4.1	13
206	Abstract 1025: Risk of diffuse large B-cell lymphoma in solid organ transplant recipients. , 2012, , .		0
207	Abstract 4490: Molecular characteristics of diffuse large B-cell lymphoma in HIV-positive and HIV-negative patients. , 2012, , .		0
208	Evolving Strategies in Epidemiologic Research on Radiation and Cancer. Radiation Research, 2011, 176, 527-532.	1.5	2
209	Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Scientific World Journal, The, 2011, 11, 2062-2070.	2.1	12
210	Variation in Effects of Non-Hodgkin Lymphoma Risk Factors According to the Human Leukocyte Antigen (HLA)-DRB1*01:01 Allele and Ancestral Haplotype 8.1. PLoS ONE, 2011, 6, e26949.	2.5	11
211	Genetic variation in Th1/Th2 pathway genes and risk of nonâ€Hodgkin lymphoma: a pooled analysis of three populationâ€based caseâ€control studies. British Journal of Haematology, 2011, 153, 341-350.	2.5	34
212	A pooled analysis of three studies evaluating genetic variation in innate immunity genes and nonâ€Hodgkin lymphoma risk. British Journal of Haematology, 2011, 152, 721-726.	2.5	29
213	Spatial-temporal analysis of non-Hodgkin lymphoma in the NCI-SEER NHL case-control study. Environmental Health, 2011, 10, 63.	4.0	27
214	Risk factors for earlyâ€onset and lateâ€onset postâ€transplant lymphoproliferative disorder in kidney recipients in the United States. American Journal of Hematology, 2011, 86, 206-209.	4.1	162
215	Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer, 2011, 117, 1163-1171.	4.1	116
216	Risk factors for nonâ€Hodgkin lymphoma subtypes defined by histology and t(14;18) in a populationâ€based caseâ€control study. International Journal of Cancer, 2011, 129, 938-947.	5.1	14

#	Article	IF	Citations
217	Hair dye use and risk of bladder cancer in the New England bladder cancer study. International Journal of Cancer, 2011, 129, 2894-2904.	5.1	52
218	Associations between non-Hodgkin lymphoma and renal cell carcinoma. Leukemia and Lymphoma, 2011, 52, 2201-2202.	1.3	4
219	Variations in Chromosomes 9 and 6p21.3 with Risk of Nonâ€"Hodgkin Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 42-49.	2.5	17
220	Proportions of Kaposi Sarcoma, Selected Non-Hodgkin Lymphomas, and Cervical Cancer in the United States Occurring in Persons With AIDS, 1980-2007. JAMA - Journal of the American Medical Association, 2011, 305, 1450.	7.4	150
221	A step toward slaying the hydra of second cancers. Nature Medicine, 2011, 17, 924-925.	30.7	11
222	A Caseâ€"Control Study of Occupational Exposure to Trichloroethylene and Non-Hodgkin Lymphoma. Environmental Health Perspectives, 2011, 119, 232-238.	6.0	51
223	GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma. PLoS Genetics, 2011, 7, e1001378.	3.5	93
224	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 245-52.	0.4	7
225	Hodgkin Lymphoma Among US Solid Organ Transplant Recipients. Transplantation, 2010, 90, 1011-1015.	1.0	29
226	Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood, 2010, 115, 4820-4823.	1.4	68
227	Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2010, 21, 127-133.	1.8	11
228	Smoking, alcohol use, obesity, and overall survival from nonâ€Hodgkin lymphoma. Cancer, 2010, 116, 2993-3000.	4.1	68
229	Polymorphisms in DNA repair genes and risk of nonâ€Hodgkin lymphoma in a pooled analysis of three studies. British Journal of Haematology, 2010, 151, 239-244.	2.5	18
230	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nature Genetics, 2010, 42, 661-664.	21.4	152
231	Mating Habits of New Zealand Dusky Dolphins. , 2010, , 151-176.		14
232	Associations Between Anthropometry, Cigarette Smoking, Alcohol Consumption, and Non-Hodgkin Lymphoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. American Journal of Epidemiology, 2010, 171, 1270-1281.	3.4	74
233	Increased Risk for Lymphoid and Myeloid Neoplasms in Elderly Solid-Organ Transplant Recipients. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1229-1237.	2.5	41
234	InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood, 2010, 116, e90-e98.	1.4	200

#	Article	IF	Citations
235	Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype. Journal of Clinical Oncology, 2010, 28, 4935-4944.	1.6	161
236	Abstract 5644: Second cancer risks among lymphoma survivors in the SEER-Medicare linked dataset. , 2010, , .		0
237	Risk of Nonâ€"Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1259-1270.	2.5	59
238	A prospective investigation of serum 25â€hydroxyvitamin D and risk of lymphoid cancers. International Journal of Cancer, 2009, 124, 979-986.	5.1	70
239	Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Healthâ€AARP Diet and Health Study Cohort. International Journal of Cancer, 2009, 124, 2737-2743.	5.1	35
240	Populationâ€based study of autoimmune conditions and the risk of specific lymphoid malignancies. International Journal of Cancer, 2009, 125, 398-405.	5.1	221
241	SLC6A3and body mass index in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. BMC Medical Genetics, 2009, 10, 9.	2.1	4
242	Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leukemia Research, 2009, 33, 1609-1614.	0.8	15
243	Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. Blood, 2009, 114, 264-267.	1.4	42
244	A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis, 2009, 30, 275-281.	2.8	75
245	Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma. Blood, 2009, 113, 1899-1905.	1.4	39
246	Common Gene Variants in the Tumor Necrosis Factor (TNF) and TNF Receptor Superfamilies and NF-kB Transcription Factors and Non-Hodgkin Lymphoma Risk. PLoS ONE, 2009, 4, e5360.	2.5	88
247	Nonâ€Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph Consortium. International Journal of Cancer, 2008, 122, 2062-2070.	5.1	104
248	Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996â€"2004. Cancer Causes and Control, 2008, 19, 1171-1181.	1.8	45
249	Blood transfusion, anesthesia, surgery and risk of nonâ€Hodgkin lymphoma in a populationâ€based caseâ€"control study. International Journal of Cancer, 2008, 123, 888-894.	5.1	18
250	Encouraging participation in medical research: what strategies work?. Journal of Clinical Epidemiology, 2008, 61, 969-970.	5.0	9
251	Hepatitis C and Non-Hodgkin Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma Epidemiology Consortium. Clinical Gastroenterology and Hepatology, 2008, 6, 451-458.	4.4	313
252	Re: Hair dye use, genetic variation in N -acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma, author response. Carcinogenesis, 2008, 29, 1084-1085.	2.8	1

#	Article	IF	Citations
253	Personal Use of Hair Dye and the Risk of Certain Subtypes of Non-Hodgkin Lymphoma. American Journal of Epidemiology, 2008, 167, 1321-1331.	3.4	98
254	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood, 2008, 112, 2694-2702.	1.4	64
255	Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood, 2008, 112, 5150-5160.	1.4	148
256	Dietary flavonoid intake and non-Hodgkin lymphoma risk. American Journal of Clinical Nutrition, 2008, 87, 1439-1445.	4.7	45
257	Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood, 2007, 110, 695-708.	1.4	365
258	Alcohol, Smoking, and Body Size in Relation to Incident Hodgkin's and Non-Hodgkin's Lymphoma Risk. American Journal of Epidemiology, 2007, 166, 697-708.	3.4	112
259	Census and Geographic Differences between Respondents and Nonrespondents in a Case-Control Study of Non-Hodgkin Lymphoma. American Journal of Epidemiology, 2007, 167, 350-361.	3.4	26
260	Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. Carcinogenesis, 2007, 28, 1759-1764.	2.8	39
261	Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. Blood, 2007, 110, 4599-4605.	1.4	35
262	Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood, 2007, 109, 5439-5446.	1.4	109
263	Immune Mechanisms in Nonâ€“Hodgkin Lymphoma: Joint Effects of the TNF G308A and IL10 T3575A Polymorphisms with Nonâ€“Hodgkin Lymphoma Risk Factors. Cancer Research, 2007, 67, 5042-5054.	0.9	57
264	Genetic variation in catechol-O-methyltransferase (COMT) and obesity in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Human Genetics, 2007, 122, 41-49.	3.8	15
265	Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenetics and Genomics, 2006, 16, 537-545.	1.5	48
266	DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Pharmacogenetics and Genomics, 2006, 16, 901-910.	1.5	46
267	Changes in Cancer Registry Coding for Lymphoma Subtypes: Reliability Over Time and Relevance for Surveillance and Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 630-638.	2.5	82
268	Reporting Participation in Epidemiologic Studies: A Survey of Practice. American Journal of Epidemiology, 2006, 163, 197-203.	3.4	420
269	Consumption of Aspartame-Containing Beverages and Incidence of Hematopoietic and Brain Malignancies. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1654-1659.	2.5	85
270	Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 2006, 107, 265-276.	1.4	1,392

#	Article	IF	Citations
271	Germline Single Nucleotide Polymorphisms (SNPs) in IL1A, IL6, IL10, and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2006, 108, 2028-2028.	1.4	0
272	Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic Lymphoma.. Blood, 2006, 108, 2396-2396.	1.4	0
273	Cigarette Smoking and Risk of Non-Hodgkin Lymphoma: A Pooled Analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 925-933.	2.5	164
274	Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncology, The, 2005, 6, 469-476.	10.7	137
275	Blood Transfusion and Risk of Non-Hodgkin's Lymphoma in Connecticut Women. American Journal of Epidemiology, 2004, 160, 325-330.	3.4	30
276	Menstrual and Reproductive Factors and Risk of Non-Hodgkin's Lymphoma among Connecticut Women. American Journal of Epidemiology, 2004, 160, 766-773.	3.4	34
277	Re: No Increased Risk of non-Hodgkin's Lymphoma with Steroids, Estrogens and Psychotropics (Netherlands). Cancer Causes and Control, 2004, 15, 433-434.	1.8	2
278	Reply to P. PetranoviÄ‡ OvÄœariÄ•k et al. Journal of Clinical Oncology, 0, , .	1.6	0